UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7015-7015

2014

Volltextzugriff (PDF)

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8051-8051

2020

Volltextzugriff (PDF)

Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1044-1044

2017

Volltextzugriff (PDF)

Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7520-7520

2017

Volltextzugriff (PDF)

Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e19041-e19041

2017

Volltextzugriff (PDF)

Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7526-7526

2018

Volltextzugriff (PDF)

The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7548-7548

2016

Volltextzugriff (PDF)

A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS7121-TPS7121

2014

Volltextzugriff (PDF)

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.8011-8011

2016

Volltextzugriff (PDF)

Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7527-7527

2016

Volltextzugriff (PDF)

ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7013-7013

2014

Volltextzugriff (PDF)

Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8580-8580

2015

Volltextzugriff (PDF)

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8522-8522

2014

Volltextzugriff (PDF)

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7018-7018

2013

Volltextzugriff (PDF)

Drawing on Expertise: Legal Decision-making and the Reception of Expert Evidence

Criminal law review, 2008-06 (6), p.443

Roberts, Andrew

2008

Volltextzugriff (PDF)

Rejecting General Acceptance, Confounding the Gate-keeper: the Law Commission and Expert Evidence

Criminal law review, 2009-08 (8), p.551-561

Roberts, Andrew

2009

Volltextzugriff (PDF)

Pre-Trial Defence Rights and the Fair Use of Eyewitness Identification Procedures

Modern law review, 2008-05, Vol.71 (3), p.331-357

Roberts, Andrew

2008

Volltextzugriff (PDF)

Ecological connectivity between the areas beyond national jurisdiction and coastal waters: Safeguarding interests of coastal communities in developing countries

Marine policy, 2019-06, Vol.104, p.90-102

2019

Volltextzugriff (PDF)

From global to regional and back again: common climate stressors of marine ecosystems relevant for adaptation across five ocean warming hotspots

Global change biology, 2016-06, Vol.22 (6), p.2038-2053

2016

Volltextzugriff (PDF)

Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome

JAMA : the journal of the American Medical Association, 2009-11, Vol.302 (17), p.1888

2009

Volltextzugriff (PDF)

Identification of IL6R and chromosome 11q13.5 as risk loci for asthma

The Lancet (British edition), 2011-09, Vol.378 (9795), p.1006-1014

2011

Volltextzugriff (PDF)

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia

Journal of clinical oncology, 2017-05, Vol.35 (15), p.1678-1685

2017

Volltextzugriff (PDF)

Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial

BMJ (Online), 2022-01, Vol.376, p.e068041

2022

Volltextzugriff (PDF)

Rapid Response Team composition, resourcing and calling criteria in Australia

Resuscitation, 2012-05, Vol.83 (5), p.563-567

2012

Volltextzugriff (PDF)

Multi-modal MRI of hippocampal morphometry and connectivity after pediatric severe TBI

Brain imaging and behavior, 2024-02, Vol.18 (1), p.159-170

2024

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control

Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib

Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study

Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study

Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)

Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL

The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study

A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) harboring 17p deletion

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL)

ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study

Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM)

Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)

Drawing on Expertise: Legal Decision-making and the Reception of Expert Evidence

Rejecting General Acceptance, Confounding the Gate-keeper: the Law Commission and Expert Evidence

Pre-Trial Defence Rights and the Fair Use of Eyewitness Identification Procedures

Ecological connectivity between the areas beyond national jurisdiction and coastal waters: Safeguarding interests of coastal communities in developing countries

From global to regional and back again: common climate stressors of marine ecosystems relevant for adaptation across five ocean warming hotspots

Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome

Identification of IL6R and chromosome 11q13.5 as risk loci for asthma

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia

Surgical fixation with K-wires versus casting in adults with fracture of distal radius: DRAFFT2 multicentre randomised clinical trial

Rapid Response Team composition, resourcing and calling criteria in Australia

Multi-modal MRI of hippocampal morphometry and connectivity after pediatric severe TBI

Suchergebnisse filtern